Depression and Mood Disorders: Clinical Reference

Depression and mood disorders represent a clinically and epidemiologically significant category of psychiatric conditions defined by sustained, pathological disturbances in affect, energy, cognition, and neurovegetative function. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), published by the American Psychiatric Association (APA), provides the primary nosological framework used across US clinical settings. This reference covers the clinical definition, neurobiological mechanics, causal drivers, diagnostic classification, contested clinical boundaries, and structured assessment components relevant to understanding this category of conditions.

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Checklist or Steps (Non-Advisory)
• Reference Table or Matrix

Definition and Scope

Mood disorders occupy a distinct position in psychiatric nosology because they are defined not by isolated symptoms but by syndrome-level patterns — clusters of affective, cognitive, somatic, and behavioral disturbances that persist beyond normal emotional variation. The DSM-5 separates this broad grouping into two primary chapters: Depressive Disorders and Bipolar and Related Disorders, a structural distinction absent from earlier editions of the manual.

The National Institute of Mental Health (NIMH) reports that major depressive disorder (MDD) affected an estimated 21 million adults in the United States in 2021, representing approximately 8.3% of the adult population. Persistent depressive disorder (dysthymia) carries a lifetime prevalence of approximately 2.5% in US adult samples, per the same NIMH statistical database.

Mood disorders are distinguished from anxiety disorders by their central defining feature: the disturbance is primarily in mood state (depressed, elevated, or mixed) rather than in threat-anticipation or fear circuitry, though comorbidity between the two categories is clinically common. For broader orientation to how mood conditions fit within psychiatric classification, see the mental health conditions overview.

The World Health Organization (WHO) classifies depressive disorders under ICD-11 block 6A70–6A7Z, providing an internationally recognized coding structure parallel to DSM-5 that US providers using ICD-10-CM coding reference for billing and epidemiological reporting.

Core Mechanics or Structure

The neurobiology of mood disorders involves dysregulation across at least three interacting systems: monoamine neurotransmission, hypothalamic-pituitary-adrenal (HPA) axis function, and neuroplasticity mechanisms centered on the hippocampus and prefrontal cortex.

Monoamine hypothesis: Historically dominant, this model proposes that deficits in serotonin, norepinephrine, and dopamine neurotransmission underlie depressive states. This model informs the mechanism of action of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), both of which are first-line pharmacological agents per the American Psychiatric Association's Practice Guideline for the Treatment of Patients with Major Depressive Disorder (Third Edition). For a structured reference on these agents, see antidepressants: types and uses.

HPA axis dysregulation: Elevated cortisol levels — produced by chronic HPA activation — are reproducibly documented in subgroups of patients with MDD. The National Institute of Mental Health has funded research establishing that hypercortisolemia correlates with hippocampal volume reduction, providing a mechanistic bridge between psychosocial stress and structural neurological change.

Neuroinflammatory model: Elevated pro-inflammatory cytokines (including interleukin-6 and tumor necrosis factor-alpha) are found at statistically elevated rates in patients with MDD compared to non-depressed controls, per meta-analytic data published in research-based journals including JAMA Psychiatry. This model is increasingly incorporated into research on treatment-resistant depression.

Circadian disruption: Sleep architecture abnormalities — particularly shortened REM latency and fragmented slow-wave sleep — are present in a substantial proportion of patients with MDD and constitute measurable biomarkers. The DSM-5 includes sleep disturbance as one of 9 diagnostic criteria for a major depressive episode.

Causal Relationships or Drivers

No single causal mechanism produces mood disorders. The diathesis-stress model, endorsed by the APA and NIMH as a heuristic framework, holds that genetic vulnerability interacts with environmental stressors to precipitate clinical episodes.

Genetic contributions: Twin studies, including the large-scale Virginia Twin Registry research conducted by Kenneth Kendler and colleagues, estimate heritability of MDD at approximately 37%. Genome-wide association studies (GWAS) have identified variants at more than 100 genomic loci associated with MDD risk, per data from the Psychiatric Genomics Consortium (PGC) published as of 2019.

Early adversity: Adverse Childhood Experiences (ACEs), catalogued in the landmark CDC-Kaiser Permanente ACE Study (1995–1997), demonstrate dose-response relationships between childhood trauma exposure and lifetime risk of depressive and mood disorders. Individuals with 4 or more ACE categories showed substantially elevated likelihood of lifetime depression relative to those with 0 ACEs, per the published study data (CDC ACE data).

Psychosocial stressors: Life events involving loss, humiliation, entrapment, or interpersonal conflict are the strongest acute precipitants of major depressive episodes across demographic groups.

Medical comorbidities: Hypothyroidism, Parkinson's disease, post-stroke states, and chronic pain conditions carry elevated rates of secondary depressive disorders. The presence of a general medical condition that can produce mood symptoms must be excluded diagnostically before a primary mood disorder diagnosis is confirmed — a requirement codified in DSM-5 Criterion C for major depressive episodes.

Substance use disorders represent a bidirectional risk factor. Depression increases the likelihood of substance misuse, and chronic substance use — particularly alcohol, stimulants, and opioids — produces neurobiological changes that can precipitate or sustain depressive states. This interaction is detailed further at substance use disorders and co-occurring mental health.

Classification Boundaries

The DSM-5 enumerates the following distinct depressive disorder categories:

• Major Depressive Disorder (MDD): 5 or more of 9 criteria symptoms present for at least 2 consecutive weeks; at least one symptom must be depressed mood or anhedonia; significant functional impairment required.
• Persistent Depressive Disorder (PDD/Dysthymia): Depressed mood for at least 2 years in adults (1 year in children/adolescents), with at least 2 of 6 associated symptoms.
• Disruptive Mood Dysregulation Disorder (DMDD): Childhood diagnosis (ages 6–18) characterized by chronic irritability and severe recurrent temper outbursts, introduced in DSM-5 to reduce overdiagnosis of pediatric bipolar disorder.
• Premenstrual Dysphoric Disorder (PMDD): Affective, behavioral, and somatic symptoms in the luteal phase of the menstrual cycle, meeting threshold severity and confirmed across at least 2 symptomatic cycles.
• Substance/Medication-Induced Depressive Disorder: Causally linked to a substance or medication.
• Depressive Disorder Due to Another Medical Condition.

The boundary separating depressive disorders from bipolar disorder is clinically significant. Bipolar II disorder — characterized by major depressive episodes and hypomania (not full mania) — is frequently misclassified as MDD, particularly when patients present during a depressive phase and do not spontaneously report prior hypomanic episodes. This misclassification has treatment consequences because antidepressant monotherapy without mood stabilization is associated with mood destabilization risk in bipolar II, per APA clinical guidelines. Mood stabilizers in mental health treatment provides a structured overview of pharmacological options relevant to this boundary.

Grief and bereavement represent a contested boundary zone. DSM-5 removed the prior "bereavement exclusion" for MDD diagnoses, permitting a concurrent or subsequent MDD diagnosis during bereavement when criteria are otherwise met. This change generated academic debate regarding medicalization of normal grief.

Tradeoffs and Tensions

Categorical vs. dimensional diagnosis: DSM-5 maintains categorical diagnoses, but the NIMH's Research Domain Criteria (RDoC) initiative (nimh.nih.gov/research/rdoc) explicitly rejects categorical diagnoses as the organizing framework for research, instead proposing continuous dimensions of function. This creates a structural tension between clinical practice frameworks and current NIMH research strategy.

Antidepressant efficacy debates: A 2008 meta-analysis by Kirsch and colleagues, published in PLOS Medicine, argued that antidepressant efficacy over placebo was clinically meaningful only in severe MDD. Subsequent meta-analyses — including Cipriani et al. (2018) in The Lancet, covering 522 trials and 116,477 participants — demonstrated statistically and clinically significant efficacy across MDD severity levels for 21 antidepressants. The two bodies of evidence are not fully reconcilable and reflect differing methodological assumptions about effect size thresholds.

Overdiagnosis concerns: Critics including physician-researchers in the field of psychiatry have argued that MDD criteria lack biological validation and that their broad, symptom-count-based structure risks diagnosing normal distress responses as disorders. The DSM-5 field trials reported kappa coefficients for MDD of approximately 0.28–0.80 across sites, indicating variable inter-rater reliability.

Underdiagnosis in specific populations: Older adults and racial/ethnic minority populations show documented patterns of underdiagnosis and undertreatment of MDD, as detailed in NIMH disparity research. The intersection of diagnosis access and structural inequality is covered at racial and ethnic disparities in mental health.

Common Misconceptions

Misconception: Depression is equivalent to sadness.
Correction: Anhedonia — the inability to experience pleasure — is equally diagnostic and in a substantial subgroup is the primary presenting symptom rather than subjective sadness. DSM-5 Criterion A requires either depressed mood or anhedonia, not both.

Misconception: Mood disorders resolve on their own without intervention in most cases.
Correction: The National Comorbidity Survey Replication (NCS-R), conducted by Harvard Medical School researchers, found that the median duration of untreated MDD episodes is approximately 16 weeks, but recurrence rates are high — approximately 50% of individuals who experience one MDD episode will experience a second; after a second episode, recurrence probability exceeds 70%, per APA treatment guidelines.

Misconception: Antidepressants work immediately.
Correction: Clinical onset of antidepressant response typically occurs over 4–6 weeks of adequate dosing. Remission — defined as near-complete resolution of symptoms — requires adequate duration at therapeutic dose, not simply initiation of therapy.

Misconception: Mood disorders are purely psychological in origin.
Correction: Neurobiological markers including hippocampal volume reduction, HPA axis dysregulation, and inflammatory cytokine elevation have been documented in MDD through research-based research published in journals including Neuropsychopharmacology and Biological Psychiatry.

Misconception: Dysthymia is a mild condition with low clinical impact.
Correction: Persistent depressive disorder, by definition lasting 2 years or more, is associated with substantial cumulative functional impairment. The NIMH classifies PDD as a clinically significant condition requiring formal assessment and evidence-based treatment consideration.

Checklist or Steps (Non-Advisory)

The following components constitute the standard clinical assessment structure for suspected mood disorder, as outlined in APA clinical practice guidelines and the DSM-5 diagnostic framework. This is a structural reference — not clinical advice.

Structured Mood Disorder Assessment Components

1. Chief complaint and timeline documentation — Record onset, duration, and episodic vs. chronic pattern of mood disturbance.
2. Symptom inventory against DSM-5 Criterion A — Screen all 9 MDD criteria: depressed mood, anhedonia, weight/appetite change, sleep disturbance, psychomotor changes, fatigue, worthlessness/guilt, concentration impairment, suicidal ideation.
3. Severity and functional impairment rating — Document occupational, social, and self-care domains of impairment; standardized tools include the PHQ-9 (NIMH-endorsed screening tools).
4. Hypomanic/manic episode screening — Assess for prior elevated mood, decreased need for sleep, increased goal-directed activity, and impulsivity to exclude bipolar spectrum conditions.
5. Medical condition exclusion — Document thyroid function (TSH), CBC, and relevant metabolic panels to rule out medical etiology per DSM-5 Criterion C.
6. Substance and medication review — Screen for substances and medications with known depressogenic effects (corticosteroids, interferons, certain antihypertensives).
7. Suicide and self-harm risk stratification — Apply structured risk assessment; suicidality as a distinct clinical concern is covered at suicidality and crisis intervention.
8. Psychiatric history and treatment response record — Document prior episodes, prior treatment agents, response, tolerability, and adherence patterns.
9. Family psychiatric history — First-degree relative history of mood disorders, bipolar disorder, and completed suicide informs both diagnosis and treatment planning.
10. Collateral information — When clinically indicated and with appropriate consent, obtain collateral from family members or prior treatment providers.

Reference Table or Matrix

DSM-5 codes reflect ICD-9-CM equivalents used in some clinical settings; ICD-10-CM codes (e.g., F32.x for MDD) are used for US billing per CMS guidelines.

References

• American Psychiatric Association — DSM-5 Overview
• National Institute of Mental Health — Major Depression Statistics
• [National Institute of Mental Health — Research Domain Criteria (RDo